Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 02, 2023

BUY
$57.89 - $64.73 $240,243 - $268,629
4,150 New
4,150 $240,000
Q1 2023

May 01, 2023

BUY
$65.71 - $74.53 $141,276 - $160,239
2,150 Added 136.08%
3,730 $258,000
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $16,702 - $18,395
230 Added 17.04%
1,580 $122,000
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $646,769 - $775,534
-10,520 Reduced 88.63%
1,350 $99,000
Q4 2021

Feb 02, 2022

BUY
$53.63 - $62.52 $13,407 - $15,630
250 Added 2.15%
11,870 $740,000
Q3 2021

Oct 29, 2021

SELL
$59.17 - $69.31 $43,785 - $51,289
-740 Reduced 5.99%
11,620 $688,000
Q2 2021

Aug 10, 2021

SELL
$61.91 - $67.42 $89,769 - $97,759
-1,450 Reduced 10.5%
12,360 $826,000
Q1 2021

May 07, 2021

BUY
$59.34 - $66.74 $356,633 - $401,107
6,010 Added 77.05%
13,810 $872,000
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $8,661 - $9,814
-150 Reduced 1.89%
7,800 $484,000
Q3 2020

Nov 02, 2020

BUY
$57.43 - $63.64 $8,614 - $9,546
150 Added 1.92%
7,950 $479,000
Q2 2020

Aug 05, 2020

SELL
$54.82 - $64.09 $413,891 - $483,879
-7,550 Reduced 49.19%
7,800 $459,000
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $47,328 - $68,778
1,020 Added 7.12%
15,350 $856,000
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $82,180 - $107,197
1,670 Added 13.19%
14,330 $920,000
Q3 2019

Nov 13, 2019

BUY
$42.77 - $50.71 $53,034 - $62,880
1,240 Added 10.86%
12,660 $642,000
Q2 2019

Aug 09, 2019

SELL
$44.62 - $49.34 $109,765 - $121,376
-2,460 Reduced 17.72%
11,420 $518,000
Q1 2019

May 07, 2019

SELL
$45.12 - $53.8 $13,987 - $16,678
-310 Reduced 2.18%
13,880 $662,000
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $691,904 - $897,233
14,190 New
14,190 $738,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Asahi Life Asset Management Co., Ltd. Portfolio

Follow Asahi Life Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asahi Life Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Asahi Life Asset Management Co., Ltd. with notifications on news.